Is VERV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VERV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate VERV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VERV's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VERV?
Key metric: As VERV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for VERV. This is calculated by dividing VERV's market cap by their current
revenue.
What is VERV's PS Ratio?
PS Ratio
16.8x
Sales
US$24.40m
Market Cap
US$410.62m
VERV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: VERV is expensive based on its Price-To-Sales Ratio (16.8x) compared to the US Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is VERV's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
VERV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
16.8x
Fair PS Ratio
0.007x
Price-To-Sales vs Fair Ratio: VERV is expensive based on its Price-To-Sales Ratio (16.8x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst VERV forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
US$4.85
US$26.20
+440.3%
31.4%
US$40.00
US$14.00
n/a
9
Nov ’25
US$5.93
US$26.01
+338.6%
28.2%
US$40.00
US$15.00
n/a
10
Oct ’25
US$4.79
US$26.01
+443.0%
28.2%
US$40.00
US$15.00
n/a
10
Sep ’25
US$6.70
US$26.01
+288.2%
28.2%
US$40.00
US$15.00
n/a
10
Aug ’25
US$6.73
US$25.78
+283.0%
27.2%
US$40.00
US$15.00
n/a
9
Jul ’25
US$4.98
US$26.89
+439.9%
28.2%
US$40.00
US$15.00
n/a
9
Jun ’25
US$5.19
US$26.89
+418.1%
28.2%
US$40.00
US$15.00
n/a
9
May ’25
US$6.00
US$31.22
+420.4%
35.1%
US$55.00
US$15.00
n/a
9
Apr ’25
US$12.79
US$48.25
+277.2%
33.0%
US$75.00
US$24.00
n/a
8
Mar ’25
US$16.29
US$48.25
+196.2%
33.0%
US$75.00
US$24.00
n/a
8
Feb ’25
US$11.21
US$45.89
+309.4%
36.0%
US$75.00
US$22.00
n/a
9
Jan ’25
US$13.94
US$45.89
+229.2%
36.0%
US$75.00
US$22.00
n/a
9
Dec ’24
US$11.79
US$46.44
+293.9%
34.3%
US$75.00
US$22.00
n/a
9
Nov ’24
US$11.75
US$46.11
+292.4%
35.3%
US$75.00
US$22.00
US$5.93
9
Oct ’24
US$13.26
US$46.11
+247.7%
35.3%
US$75.00
US$22.00
US$4.79
9
Sep ’24
US$13.45
US$41.73
+210.2%
42.7%
US$75.00
US$13.00
US$6.70
11
Aug ’24
US$19.42
US$42.00
+116.3%
42.4%
US$75.00
US$13.00
US$6.73
11
Jul ’24
US$18.75
US$42.00
+124.0%
42.4%
US$75.00
US$13.00
US$4.98
11
Jun ’24
US$15.41
US$41.82
+171.4%
43.1%
US$75.00
US$13.00
US$5.19
11
May ’24
US$16.04
US$42.27
+163.5%
41.7%
US$75.00
US$14.00
US$6.00
11
Apr ’24
US$14.42
US$42.60
+195.4%
41.3%
US$75.00
US$14.00
US$12.79
10
Mar ’24
US$18.19
US$42.40
+133.1%
41.4%
US$75.00
US$13.00
US$16.29
10
Feb ’24
US$22.07
US$42.40
+92.1%
41.4%
US$75.00
US$13.00
US$11.21
10
Jan ’24
US$19.35
US$44.78
+131.4%
37.7%
US$75.00
US$13.00
US$13.94
9
Dec ’23
US$22.57
US$49.50
+119.3%
28.1%
US$75.00
US$35.00
US$11.79
8
Nov ’23
US$36.44
US$53.13
+45.8%
21.3%
US$75.00
US$36.00
US$11.75
8
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.